​

CRISPR Therapeutics (CRSP) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

CRSP Stock Forecast

CRISPR Therapeutics (CRSP) stock forecast, based on 37 Wall Street analysts, predicts a 12-month average price target of $66.33, with a high of $75.00 and a low of $50.00. This represents a 14.20% increase from the last price of $58.08.

$35 $45 $55 $65 $75 $85 High: $75 Avg: $66.33 Low: $50 Last Closed Price: $58.08

CRSP Stock Rating

CRISPR Therapeutics stock's rating consensus is Buy, based on 37 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 21 Buy (56.76%), 13 Hold (35.14%), 3 Sell (8.11%), and 0 Strong Sell (0.00%).

Buy
Total 37 3 13 21 0 Strong Sell Sell Hold Buy Strong Buy

CRSP Price Target Upside V Benchmarks

TypeNameUpside
StockCRISPR Therapeutics14.20%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts134
Avg Price Target$74.00$66.33$66.00
Last Closing Price$58.08$58.08$58.08
Upside/Downside27.41%14.20%13.64%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Dec, 25512101-28
Nov, 2569101-26
Oct, 2569101-26
Sep, 25511101-27
Aug, 25610101-27
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Nov 26, 2025Chardan Capital$74.00$52.7940.18%27.41%
Nov 11, 2025Luca IssiRBC Capital$50.00$54.58-8.39%-13.91%
Oct 13, 2025Yanan ZhuWells Fargo$75.00$73.102.60%29.13%
Feb 03, 2025Mitchell KapoorH.C. Wainwright$65.00$40.0062.50%11.91%
Nov 06, 2024Jay OlsonOppenheimer$95.00$49.5191.88%63.57%
Nov 05, 2024Rick BienkowskiLeerink Partners$67.00$50.3633.04%15.36%
Aug 12, 2024Joon LeeTruist Financial$100.00$46.55114.82%72.18%
Aug 06, 2024Gil BlumNeedham$84.00$50.1167.63%44.63%
Aug 06, 2024Benjamin BurnettStifel Nicolaus$59.00$50.0117.98%1.58%
Aug 06, 2024Luca IssiRBC Capital$60.00$50.1319.69%3.31%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Nov 12, 2025CitigroupBuyBuyhold
Nov 11, 2025CitigroupMarket OutperformMarket Outperformhold
Nov 11, 2025RBC CapitalSector PerformSector Performhold
Nov 05, 2024Leerink PartnersOutperformOutperformhold
Aug 06, 2024Cowen & Co.SellSellhold
Aug 06, 2024NeedhamBuyBuyhold
Aug 06, 2024RBC CapitalSector PerformSector Performhold
Jun 17, 2024Piper SandlerOverweightOverweighthold
Apr 18, 2024CitigroupBuyBuyhold
Feb 15, 2024Wolfe ResearchPeer Performinitialise

Financial Forecast

EPS Forecast

$-50 $-31 $-12 $7 $26 $45 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-5.29$4.97$-8.36$-1.94$-4.34----
Avg Forecast$-5.02$4.88$-9.09$-2.92$-5.17$-5.07$-3.12$-1.00$1.71
High Forecast$0.70$44.49$2.49$-1.60$-4.73$-3.01$8.56$9.76$7.17
Low Forecast$-45.76$-0.68$-36.12$-4.16$-6.53$-6.60$-7.69$-5.76$-0.47
Surprise %5.38%1.84%-8.03%-33.56%-16.05%----

Revenue Forecast

$0 $1B $3B $4B $6B $7B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$543.00K$913.08M$436.00K$371.21M$37.31M----
Avg Forecast$2.32M$903.86M$6.14M$293.21M$11.13M$118.69M$506.62M$1.02B$1.69B
High Forecast$16.78M$6.54B$20.20M$377.05M$36.07M$410.38M$516.62M$1.04B$5.85B
Low Forecast$287.31K$112.01M$122.50K$173.24M$1.21M$2.49M$496.61M$1.01B$35.48M
Surprise %-76.58%1.02%-92.90%26.60%235.12%----

Net Income Forecast

$-1B $-600M $-200M $200M $600M $1B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-348.87M$377.66M$-650.17M$-153.61M$-366.25M----
Avg Forecast$-282.52M$338.20M$-603.01M$-153.61M$-445.92M$-448.97M$-262.09M$-119.23M$135.47M
High Forecast$-226.02M$554.59M$-482.41M$-122.89M$-374.41M$-238.06M$678.45M$773.32M$568.30M
Low Forecast$-339.03M$121.81M$-723.61M$-184.33M$-517.43M$-522.52M$-609.51M$-456.49M$-36.95M
Surprise %23.48%11.67%7.82%--17.87%----

CRSP Forecast FAQ

Is CRISPR Therapeutics stock a buy?

CRISPR Therapeutics stock has a consensus rating of Buy, based on 37 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 21 Buy, 13 Hold, 3 Sell, and 0 Strong Sell, reflecting a consensus that CRISPR Therapeutics is a favorable investment for most analysts.

What is CRISPR Therapeutics's price target?

CRISPR Therapeutics's price target, set by 37 Wall Street analysts, averages $66.33 over the next 12 months. The price target range spans from $50 at the low end to $75 at the high end, suggesting a potential 14.20% change from the previous closing price of $58.08.

How does CRISPR Therapeutics stock forecast compare to its benchmarks?

CRISPR Therapeutics's stock forecast shows a 14.20% upside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for CRISPR Therapeutics over the past three months?

  • December 2025: 17.86% Strong Buy, 42.86% Buy, 35.71% Hold, 3.57% Sell, 0% Strong Sell.
  • November 2025: 23.08% Strong Buy, 34.62% Buy, 38.46% Hold, 3.85% Sell, 0% Strong Sell.
  • October 2025: 23.08% Strong Buy, 34.62% Buy, 38.46% Hold, 3.85% Sell, 0% Strong Sell.

What is CRISPR Therapeutics’s EPS forecast?

CRISPR Therapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $-5.07, marking a 16.82% increase from the reported $-4.34 in 2024. Estimates for the following years are $-3.12 in 2026, $-1 in 2027, and $1.71 in 2028.

What is CRISPR Therapeutics’s revenue forecast?

CRISPR Therapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $118.69M, reflecting a 218.07% increase from the reported $37.31M in 2024. The forecast for 2026 is $506.62M, followed by $1.02B for 2027, and $1.69B for 2028.

What is CRISPR Therapeutics’s net income forecast?

CRISPR Therapeutics's net income forecast for the fiscal year ending in December 2025 stands at $-449M, representing an 22.58% increase from the reported $-366M in 2024. Projections indicate $-262M in 2026, $-119M in 2027, and $135.47M in 2028.